BioCentury
ARTICLE | Clinical News

MG98: Began Phase I study

March 22, 1999 8:00 AM UTC

MethylGene Inc., Montreal, Quebec Product: MG98 Business: Cancer Therapeutic category: Antisense Target: DNA methyltransferase Description: Second generation antisense oligonucleotide targeting the ...